Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/213058
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the PREDIMED Trial |
Autor: | Basterra-Gortari, F. Javier; Ruiz-Canela, Miguel; Martínez-González, Miguel Ángel; Babio, Nancy; Sorlí, José V.; Fitó, Montserrat; Ros, Emilio; Gómez-Gracia, Enrique; Fiol, Miquel; Lapetra, José; Estruch, Ramón; Serra-Majem, Lluis; Pintó, Xavier; González, José I.; Bulló, Mònica; Castañer, Olga; Alonso-Gómez, Ángel M.; Forga, Luis; Arós, Fernando | Fecha de publicación: | ago-2019 | Editor: | American Diabetes Association | Citación: | Diabetes Care 42(8): 1390 (2019) | Resumen: | [Objective]: To examine the effects of two Mediterranean eating plans (Med-EatPlans) versus a low-fat eating plan on the need for glucose-lowering medications. [Research design and methods]: From the Prevención con Dieta Mediterránea (PREDIMED) trial, we selected 3,230 participants with type 2 diabetes at baseline. These participants were randomly assigned to one of three eating plans: Med-EatPlan supplemented with extra-virgin olive oil (EVOO), Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan (control). In a subgroup (15%), the allocation was done in small clusters instead of using individual randomization, and the clustering effect was taken into account in the statistical analysis. In multivariable time-to-event survival models, we assessed two outcomes: 1) introduction of the first glucose-lowering medication (oral or injectable) among participants on lifestyle management at enrollment and 2) insulin initiation. [Results]: After a median follow-up of 3.2 years, in multivariable analyses adjusting for baseline characteristics and propensity scores, the hazard ratios (HRs) of starting a first glucose-lowering medication were 0.78 (95% CI 0.62–0.98) for Med-EatPlan + EVOO and 0.89 (0.71–1.12) for Med-EatPlan + nuts, compared with the control eating plan. After a median follow-up of 5.1 years, the adjusted HRs of starting insulin treatment were 0.87 (0.68–1.11) for Med-EatPlan + EVOO and 0.89 (0.69–1.14) for Med-EatPlan + nuts compared with the control eating plan. [Conclusions]: Among participants with type 2 diabetes, a Med-EatPlan + EVOO may delay the introduction of new-onset glucose-lowering medications. The Med-EatPlan did not result in a significantly lower need for insulin. | Versión del editor: | http://dx.doi.org/10.2337/dc18-2475 | URI: | http://hdl.handle.net/10261/213058 | DOI: | 10.2337/dc18-2475 | ISSN: | 0149-5992 | E-ISSN: | 1935-5548 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
16
checked on 06-abr-2024
SCOPUSTM
Citations
34
checked on 23-abr-2024
WEB OF SCIENCETM
Citations
27
checked on 22-feb-2024
Page view(s)
130
checked on 24-abr-2024
Download(s)
19
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.